EHA 2026: Comparable Outcomes with Reduced-Dose Treosulfan
/ Johanne Skovgaard Schovsbo
TP53 Mutations as a Predictive Biomarker in High-Risk Breast Cancer
/ Mari Eskild Rasmussen
Patients Take Center Stage at EHA 2026
/ Jan Andreasen
EHA 2026: Circulating Tumor Plasma Cells Predict Progression in Smoldering Myeloma
/ Sigrun Thorsteinsdottir
AI-Based Extraction of Retrospective Pathology Data for Breast Cancer Research
/ Agnar Martin Bjørnstad











